As FRANCE 24 marks World Cancer Day, François Picard welcomes Lars Henning Milman Engelholm, Associate Professor and Group Leader at the Finsen Laboratory, Rigshospitalet / Biotech Research & Innovation Centre (BRIC), University of Copenhagen. From his lab in Copenhagen, Professor Engelholm describes a seismic shift underway in pancreatic cancer research, the result of a decade-long commitment to the steady evolution of translational science.
At the heart of this shift are antibody-drug conjugates (ADCs): highly targeted therapies designed to reach what conventional treatments cannot. Engelholm’s approach focuses on the complex biology of pancreatic tumours, where cancer cells are supported by surrounding stromal cells. His work highlights the vital role of university-led research in areas the pharmaceutical industry often deems too uncertain or unprofitable to pursue.
